SCHEMBL6094592

SCHEMBL6094592

CCOC(=O)c1nn(C)c(-c2c(Cl)cccc2Cl)c1N

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
KDM4E B2RXH2 4/20 0.51
HPGD P15428 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PDE4B Q07343 3/20 0.45
PDE4A P27815 2/20 0.45
PDE4C Q08493 2/20 0.45
PDE4D Q08499 2/20 0.45
ADORA1 P30542 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
ADORA2A P29274 1/20 0.43
GAA P10253 1/20 0.42
ELANE P08246 2/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1753231 0.81 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL7227582 0.80 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDHSD17B10L3MBTL1
SCHEMBL7500603 0.75 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDHSD17B10L3MBTL1
SCHEMBL15569276 0.72 TSHR (0.49) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL15884064 0.72 GABRG2 (0.48) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL4816797 0.72 PDE4B (0.53) ALDH1A1KDM4EHPGDHSD17B10PDE4B
SCHEMBL12683108 0.72 GRM5 (0.47) ALDH1A1KDM4EHPGDHSD17B10ELANE
SCHEMBL11409217 0.71 ALDH1A1 (0.49) ALDH1A1KDM4EHPGDMAPK1L3MBTL1
SCHEMBL15884074 0.71 GABRG2 (0.45) ALDH1A1KDM4EHPGDHSD17B10MAPK1
SCHEMBL982676 0.70 KMT2A (0.57) ALDH1A1KDM4EHSD17B10MAPK1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074929-B2 Certain alkylene diamine-substituted heterocycles NEUROGEN CORP. (US) 2006-07-11 US disclosed
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2004-11-18 US disclosed
US-6696445-B2 NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2004-02-24 US disclosed
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2003-08-21 US disclosed
US-6506762-B1 Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating NEUROGEN CORPORATION 2003-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R ALDH1A1 4696/4885KDM4E 855/4885HPGD 1838/4885
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R ALDH1A1 4696/4885KDM4E 714/4885HPGD 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.